48
views
0
recommends
+1 Recommend
3 collections
    0
    shares
       
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Traditional Chinese medicine combined with recombinant interferon to alleviate symptoms of COVID-19 infectious pneumonia

      Preprint
      In review
      research-article
      Bookmark

            Abstract

            Objectives: Collect and analyze the basic information, symptoms, therapeutic method and therapeutic effect of novel coronavirus (COVID-19) infected pneumonia patients in the hospital in northern Henan Province from January 2020 to April 2020, to provide evidences for prevention and treatment of COVID-19 infectious pneumonia. Methods: The information of patients of COVID-19 infectious pneumonia in the hospital were collected and analyzed, including the admission time, the discharge time, therapeutic method, and therapeutic effect after treatment. Results: A total of 10 cases patients of COVID-19 infectious pneumonia were collected, there were 5 male patients and 5 female patients, the age ranged from 16-54 years old and the average age was 34.2 years old; the body temperature of 6 cases patients were higher than 37°C when they were admitted to hospital; CT results showed that all the patients had infectious lesions of both lungs, and the results of nucleic acid test were positive. 5 million (aerosol inhalation) recombinant interferon (Lopinavir/Ritonavir or Lopinavir/Ritonavir/Abidol) combined with traditional Chinese medicine could alleviate effectively symptoms of COVID-19 infectious pneumonia within a month, the body temperature of patients returned to normal, respiratory symptoms improved significantly, COVID-19 nucleic acid test was negative, and results of lung imaging was also normal. Conclusion: Lopinavir/Ritonavir or Lopinavir/Ritonavir/Abidol combined with Traditional Chinese medicine has a good effect on relieving the symptoms of COVID-19 infected pneumonia and has significance for clinical treatment or clinic remission of COVID-19 infectious pneumonia.

            Content

            Author and article information

            Journal
            ScienceOpen Preprints
            ScienceOpen
            18 January 2022
            Affiliations
            [1 ] Clinic laboratory of the third people's Hospital of Hebi
            [2 ] Guangdong nephrotic drug EngineeringTechnology Research Center, Guangdong Consun Pharmaceutical Group
            Author notes
            Article
            10.14293/S2199-1006.1.SOR-.PPOVB2Y.v1
            24cead1c-d2d2-4b08-ad37-a54e1795f8ed

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            Funding
            None None

            The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
            Medicine
            COVID-19,recombinant interferon,Traditional Chinese medicine,Lopinavir/Ritonavir,Corona virus

            Comments

            Comment on this article